Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study

Table 3 Outcomes according to types of EGFR mutation and tyrosine kinase inhibitors

	Type of EGFR mutation	Type of TKI	M	p*	Type of TKI	Type of EGFR mutation	M	p*
Median PFS	Exon 19 deletion	1^st generation	12.0	0.868	1^st generation	Exon 19 deletion	12.0	0.031
	Exon 19 deletion	Afatinib	12.0			Others	9.0	0.031
	Others	1^st generation	9.0	0.042	Afatinib	Exon 19 deletion	12.0	0.305
	Others	Afatinib	15.0			Others	15.0	0.305
Median OS	Exon 19 deletion	1^st generation	28.0	0.361	1^st generation	Exon 19 deletion	28.0	0.045
	Exon 19 deletion	Afatinib	31.0			Others	19.0	0.045
	Others	1^st generation	19.0	0.069	Afatinib	Exon 19 deletion	31.0	0.604
	Others	Afatinib	27.0			Others	27.0	0.604

EGFR Epidermal growth factor receptor, TKI Tyrosine kinase inhibitor, M months (median), p p-value, OS Overall survival, PFS Progression-free survival
^*Log-rank test

ISSN: 1471-2407